Results 161 to 170 of about 616 (213)

Long-Term Real-World Outcomes in Patients with Hereditary Angioedema Receiving Lanadelumab for 3 or More Years.

open access: yesInt Arch Allergy Immunol
Lumry WR   +8 more
europepmc   +1 more source

Centralized care model for hereditary angioedema overcomes geographical barriers. [PDF]

open access: yesFront Immunol
Holmes A   +5 more
europepmc   +1 more source

Effective long-term prophylaxis with lanadelumab in adolescents with hereditary angioedema: EMPOWER/ENABLE. [PDF]

open access: yesPediatr Allergy Immunol
Tachdjian R   +11 more
europepmc   +1 more source

Therapeutic Potential of C1-Inhibitor in Vascular Diseases and Beyond. [PDF]

open access: yesArterioscler Thromb Vasc Biol
Sundler Björkman L   +2 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy